梯瓦制药 2026年季度报告

For the quarterly period ended June 30, 2026OR TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Not Applicable(IRS EmployerIdentification Number) Israel(State or other jurisdiction ofincorporation or organization) 400 Interpace Parkway, #3Parsippany NJ, 07054 USA+1-973-658-0301(Address of principal executive offices, zip code and telephone number, including area code) Securities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or forsuch shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of thischapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Large accelerated filer☒Non-accelerated filer☐Emerginggrowthcompany☐ Acceleratedfiler☐Smallerreportingcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ As of June30, 2026, the registrant had 1,165,296,084 ordinary shares outstanding. TEVA PHARMACEUTICAL INDUSTRIES LIMITED For an accessible version of this Quarterly Report on Form10-Q, please visit www.tevapharm.com INDEX PARTI.Financial Statements (unaudited)Item 1.Financial Statements (unaudited)Consolidated Balance SheetsConsolidated Statements of Income (loss)Consolidated Statements of Comprehensive Income (loss)Consolidated statements of changes in equityConsolidated Statements of Cash FlowsNotes to Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures about Market RiskItem 4.Controls and ProceduresPARTII.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures TEVA PHARMACEUTICAL INDUSTRIES LIMITED INTRODUCTION AND USE OF CERTAIN TERMS Unless otherwise indicated, all references to the “Company,” “we,” “our” and “Teva” refer to Teva Pharmaceutical Industries Limited and itssubsidiaries, and references to “revenues” refer to net revenues. References to “U.S. dollars,” “dollars,” “U.S. $” and “$” are to the lawful currency ofthe United States of America, and references to “NIS” are to new Israeli shekels. References to “ADS(s)” are to Teva’s American Depositary Share(s).Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceuticalindustry (“IQVIA”), unless otherwise stated. References to “R&D” are to Research and Development, references to “IPR&D” are to in-process R&D,references to “S&M” are to Selling and Marketing and references to “G&A” are to General and Administrative. Some amounts in this report may notadd up due to rounding. All percentages have been calculated using unrounded amounts. This report on Form 10-Q contains many of the trademarks andtrade names used by Teva in the United States and internationally to distinguish its products and services. Any third-party trademarks mentioned in thisreport are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical information, this Quarterly Report on Form 10-Q, and the reports and documents incorporated by reference in thisQuarterly Report on Form 10-Q, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, thatcould cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.These forward-looking statements include statements concerningour plans, strategies, objectives, future performance and financial and operatingtargets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as“should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “transition” and other words and termsof similar